As EMA renews its focus on ISO IDMP delivery, life sciences organisations targeting European markets must now step up their own measures to ensure they are compliant by 2021. Acknowledging the considerable task ahead of them, Siniša Belina of AMPLEXOR proposes a practical way forward.

[wonderplugin_pdf src=”https://www.biopharmaceuticalmedia.com/wp-content/uploads/2019/11/IDMP_-Back-on-Track-and-Bearing-Down-with-New-Urgency.pdf” width=”100%” height=”900px” style=”border:0;”]